DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research note issued to investors on Friday. The brokerage set a “hold” rating on the stock.

DBVT has been the subject of several other reports. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of DBV Technologies in a research note on Tuesday, September 24th. HC Wainwright raised their target price on shares of DBV Technologies from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Thursday, October 24th.

DBV Technologies Stock Down 3.9 %

Shares of DBVT stock opened at $0.47 on Friday. The stock has a market cap of $45.26 million, a price-to-earnings ratio of -0.52 and a beta of 0.66. The business’s fifty day moving average is $0.70 and its 200 day moving average is $0.85. DBV Technologies has a twelve month low of $0.44 and a twelve month high of $2.14.

Shares of DBV Technologies are going to reverse split on Friday, November 29th. The 1-5 reverse split was announced on Monday, November 11th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, November 28th.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently raised its position in DBV Technologies stock. Yiheng Capital Management L.P. boosted its position in shares of DBV Technologies S.A. (NASDAQ:DBVT) by 6.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 5,568,909 shares of the company’s stock after purchasing an additional 327,345 shares during the quarter. DBV Technologies comprises about 0.2% of Yiheng Capital Management L.P.’s holdings, making the stock its 15th biggest holding. Yiheng Capital Management L.P. owned 2.89% of DBV Technologies worth $4,172,000 at the end of the most recent reporting period. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.